Faculty profile
Tony Reiman
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
Journal of Thoracic Oncology · 2011
Latest funding
- $1,197,227
RATIONAL (Role of Antibiotic Therapy or Immunoglobulin On iNfection in hAematoLogy) Platform Trial: An RCT of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients with acquired hypogammaglobulinemia secondary to haematological malignancies
CIHR · 2024 · Principal investigator
- $3,056,172
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
CIHR · 2023 · Co-investigator
- $3,056,176
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
CIHR · 2023 · Co-investigator
1 publications.
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F
RATIONAL (Role of Antibiotic Therapy or Immunoglobulin On iNfection in hAematoLogy) Platform Trial: An RCT of continuing immunoglobulin therapy, or stopping with or without prophylactic antibiotics, on infection rate in patients with acquired hypogammaglobulinemia secondary to haematological malignancies
Principal investigators: Callum, Jeannie L; Reiman, Tony
Keywords: Adaptive Platform Trial; Antibiotic Therapy; Hematologic Malignancies; Hypogammaglobulinemia; Immunoglobulin; Infections
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
Principal investigators: Hay, Annette; Mian, Hira
Keywords: De-Escalation; Economic Analysis; Multiple Myeloma; Quality Of Life; Randomized Phase Iii Trial
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
Principal investigators: Hay, Annette; Bramson, Jonathan L; Delisle, Jean-Sébastien; Leblanc, Richard; Quizi, Jennifer L
Keywords: Biomanufacturing; Cancer; Cell Therapy; Clinical Trial; First-In-Human; Immunotherapy; Multiple Myeloma; Relapsed And Refractory; Synthetic Androgen Receptor
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- John Goffin and Lesley Seymour: 9 shared papers
- John Goffin and Tony Reiman: 1 shared paper
- Lesley Seymour and Tony Reiman: 1 shared paper
- Pathology and Molecular Medicine
- Oncology
- Other
Co-authors at Queen's University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.